|
Market Closed -
Nasdaq Stockholm
17:00:00 02/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 19.92 SEK | -2.59% |
|
+4.73% | -11.86% |
| 08-28 | Synact Pharma to present new preclinical data for resomelagon at WCI | FW |
| 08-20 | SynAct Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 119M | - | - | - | - | - |
| 1,034B | |||||
| 654B | - | - | |||
| 459B | |||||
| 343B | |||||
| 307B |
- Stock Market
- Stocks
- SYNACT Stock
- Charts SynAct Pharma AB
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
